The FDA last week approved AbbVie’s Skyrizi for the treatment of adults with active psoriatic arthritis. The news comes just days after Rinvoq, another AbbVie drug, scored an atopic dermatitis win. This will be the monoclonal antibody’s second indication. For the treatment of psoriasis, Skyrizi holds covered or better status for 98% of all insured lives in the U.S. Under the pharmacy benefit, 36% of covered lives have preferred access to Skyrizi.
SOURCE: MMIT Analytics, as of 1/26/22